Press Releases

If you want to subscribe to our press releases please go to the Cision site where it is possible to subscribe.

Note: After January 21, 2020, all press releases are published in English as original language.

ExpreS2ion publishes investor video presentation

Non-regulatory pressrelease

Hørsholm, Denmark, September 27, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that a filmed company presentation by CEO Bent U. Frandsen at Aktiedagen Lund in which he presents provides an update on ExpreS2ion’s powerful technology platform for vaccine development, pipeline projects, and key financial figures, is now available on the…

Read more

Pareto publishes research report setting price target of SEK 25 per share as new analyst assumes coverage

Non-regulatory pressrelease

Hørsholm, Denmark, September 22, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Pareto Securities has published a new research report on ExpreS2ion in September in which a new analyst, Marietta Miemietz, assumes coverage of the Company. 

Read more

ExpreS2ion will participate in key industry and investor events

Non-regulatory pressrelease

Hørsholm, Denmark, September 20, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate and hold presentations at key industry and investor events in the coming month. These include PIVAC-22, a forum covering the most recent advances in cancer immunotherapy (September 26-28), and Aktiedagen Lund (September 26).

Read more

ExpreS2ion announces full exercise of 2019 warrant program

Regulatory pressrelease

Hørsholm, Denmark, September 7, 2022 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces that 308,268 warrants held by employees under the 2019 Warrant Program (“TO2”) have been fully exercised, providing ExpreS2ion SEK 1,482,769. The exercise has increased the number of shares by 308,268 from 37,298,528 to 37,606,796. All 612,084 TO2 warrants have now been exercised,…

Read more

First subject vaccinated in COVID-19 Phase III clinical trial for ABNCoV2 as a booster vaccine

Regulatory pressrelease

Hørsholm, Denmark, September 2, 2022 – ExpreS[2]ion Biotech Holding AB’s affiliate ExpreS[2]ion Biotechnologies ApS (“ExpreS[2]ion") announces that a Phase III clinical trial to evaluate the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 vaccine has been initiated by Bavarian Nordic, including the vaccination of the first subject. The trial aims to demonstrate non-inferiority of ABNCoV2 as…

Read more

ExpreS2ion announces financial results for the second quarter 2022

Regulatory pressrelease

Hørsholm, Denmark, August 18, 2022 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its second quarter financial results for 2022. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.

Read more

ExpreS2ion will participate in key industry and investor events

Non-regulatory pressrelease

Hørsholm, Denmark, August 15, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate and hold presentations at key industry and investor events in the coming month. These include a presentation of Q2 2022 results (August 18), the LSX Nordic Investor Conference (September 6-7), and PIVAC-22, a forum covering the most recent…

Read more

ExpreS2ion announces exercise of 2019 warrant program, second tranche of three

Regulatory pressrelease

Hørsholm, Denmark, August 10, 2022 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces that 136,422 warrants held by employees under the 2019 Warrant Program (“TO2”) have been fully exercised, providing ExpreS2ion SEK 656,190. The exercise has increased the number of shares by 136,422 from 37,162,106 to 37,298,528.

Read more

ExpreS2ion announces exercise of 2019 warrant program

Non-regulatory pressrelease

Hørsholm, Denmark, July 11, 2022 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces that 167,394 warrants held by employees under the 2019 Warrant Program (“TO2”) have been fully exercised, providing ExpreS2ion SEK 805,165. The exercise has increased the number of shares by 167,394 from 36,994,712 to 37,162,106.

Read more

Updated Phase III trial for the ABNCoV2 COVID-19 vaccine to include a licensed mRNA vaccine

Regulatory pressrelease

Hørsholm, Denmark, June 16, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Bavarian Nordic’s upcoming Phase III clinical trial to evaluate the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 vaccine has been redesigned due to a licensed mRNA vaccine now being available as a comparator vaccine. This enables the design…

Read more

Analysguiden publishes research report setting price target of SEK 30 with an optimistic fair value of SEK 60

Non-regulatory pressrelease

Hørsholm, Denmark, June 13, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Analysguiden has updated their research reports on ExpreS2ion in June, following the publication of Q1 2022 results, the positive Phase II COVID-19 results for the ABNCoV2 vaccine with respect to omicron protection, and progression of the preclinical-stage breast…

Read more

ExpreS2ion publishes video presentation

Non-regulatory pressrelease

Hørsholm, Denmark, June 1, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that a filmed company presentation by CFO Keith Alexander and Vice President of Preclinical Development Mette Thorn in which they provide an update on ExpreS2ion’s breast cancer vaccine candidate, ES2B-C001, is now available on the company’s website.

Read more

ExpreS2ion announces financial results for the first quarter 2022

Regulatory pressrelease

Hørsholm, Denmark, May 31, 2022 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its first quarter financial results for 2022. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.

Read more

Announcement from ExpreS2ion's annual general meeting

Regulatory pressrelease

The annual general meeting 2022 ("AGM") of ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") was held today on 25 May 2022. The AGM was carried out through advance voting (postal voting) pursuant to temporary legislation and the following resolutions were passed by the meeting.

Read more

Scientific publication by AdaptVac researchers about a capsid virus-like particle-based vaccine targeting IL-1β for treatment of allergic contact dermatitis

Non-regulatory pressrelease

Hørsholm, Denmark, May 25, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the scientific journal Vaccines published an article authored by AdaptVac researchers about a capsid virus-like particle-based vaccine targeting IL-1β for treatment of allergic contact dermatitis.

Read more

Additional positive preclinical proof-of-concept results for the HER2-cVLP breast cancer vaccine

Regulatory pressrelease

Hørsholm, Denmark, May 25, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the capsid virus-like particle (cVLP) HER2-breast cancer vaccine candidate ES2B-C001 has demonstrated additional positive proof-of-concept also in a metastatic outgrowth therapeutic tumor mice model. These data support the already established preclinical proof-of-concept results announced in December 2021 (https://news.cision.com/expres2ion-biotechnologies/r/expres2ion-announces-positive-topline-results-for-its-her2-cvlp-breast-cancer-vaccine--demonstrating,c3476944) and…

Read more

ExpreS2ion will participate in key industry and investor events

Non-regulatory pressrelease

Hørsholm, Denmark, May 24, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate and hold presentations at key industry and investor events in the coming month. These include an Oncology webinar (May 31) and presentation of Q1 2022 results (June 9), both hosted by H.C. Andersen Capital, the ECI Vaccine Technology…

Read more

Scientific article about the advantageous S2-based protein secretion system ExpreS2 and a moderate-throughput research variant called FAS2FURIOUS

Non-regulatory pressrelease

Hørsholm, Denmark, May 9, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Frontiers in Bioengineering and Biotechnology published an article about the ability of S2 cells to express challenging targets.

Read more

ExpreS2ion announces final outcome of fully guaranteed rights issue of approximately SEK 73 million

Regulatory pressrelease

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. INSIDE…

Read more

Positive Omicron data from the COVID-19 Phase II trial reported for the ABNCoV2 vaccine

Regulatory pressrelease

Hørsholm, Denmark, May 5, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that additional positive results for the ABNCoV2 vaccine, that is being developed as a universal booster vaccine, has been reported from the Phase II clinical trial conducted by Bavarian Nordic. The new study data demonstrates a significant boost to…

Read more

ExpreS2ion - Annual report for 2021 published

Regulatory pressrelease

Hørsholm, Denmark, May 04, 2022 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that the company's annual report for the financial year 2021 is published. The annual report is available as an attachment and on ExpreS2ion's website at the following address (https://investor.expres2ionbio.com/reports/).

Read more

Notice of Annual General Meeting in ExpreS2ion Biotech Holding AB

Regulatory pressrelease

The shareholders of ExpreS2ion Biotech Holding AB, reg. no. 559033-3729, (the "Company"), are hereby convened to the annual general meeting to be held on Wednesday 25 May 2022.

Read more

ExpreS2ion publishes video presentation

Non-regulatory pressrelease

Hørsholm, Denmark, April 20, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that a filmed company presentation by CEO Bent U. Frandsen in which he presents provides an update on ExpreS2ion’s powerful platform for vaccine development, updates on the pipeline and progress towards key catalysts and the 2022 Rights Issue, is…

Read more

Frontiers in Immunology publishes article about ABNCoV2

Non-regulatory pressrelease

Hørsholm, Denmark, April 19, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Frontiers in Immunology published an article about the high level of antibodies induced by the ABNCoV2 COVID-19 vaccine in non-human primates.

Read more

ExpreS2ion publishes prospectus in connection with fully guaranteed rights issue of approximately SEK 73 million

Regulatory pressrelease

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm,…

Read more

Pareto Securities publishes research report revising price target to SEK 86

Non-regulatory pressrelease

Hørsholm, Denmark, April 8, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Pareto Securities has updated their analysis of ExpreS2ion following the announcement that the Company will be conducting a Rights Issue. Pareto reiterated its ‘buy’ rating and reduced its target price to SEK 86 per share after incorporating the…

Read more

ExpreS2ion will participate in key industry and investor events

Non-regulatory pressrelease

Hørsholm, Denmark, April 7, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate and hold presentations at key industry and investor events in the coming month. These include the World Vaccine Congress (April 18-21), a Q&A session covering the 2022 Rights Issue (April 25), Økonomisk Ugebrev Life Science Investor Conference (April…

Read more

ExpreS2ion announces a fully guaranteed rights issue of approximately SEK 73 million

Regulatory pressrelease

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. INSIDE…

Read more

AdaptVac wins EY’s 2021 Entrepreneur of the Year Award in the Danish Life Sciences category

Non-regulatory pressrelease

Hørsholm, Denmark, March 25, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that 34%-owned associated company AdaptVac ApS has won EY’s prestigious Entrepreneur of the Year 2021 award in the Life Sciences category for Denmark.

Read more

ExpreS2ion publishes video from company presentation at Aktiespararna’s Aktiedagen

Non-regulatory pressrelease

Hørsholm, Denmark, March 15, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that a filmed company presentation by CEO Bent U. Frandsen at the Aktiespararna Aktiedagen investor event on March 14, 2022 is now available on the company’s website.

Read more

ExpreS2ion will participate at key industry and investor events in March 2022

Non-regulatory pressrelease

Hørsholm, Denmark, March 9, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate and hold presentations at key industry and investor events in March. These include Aktiespararna’s Aktiedagen (March 14), the Swiss Nordic Bio event (March 23), and BIO-Europe Spring (March 28-31).

Read more

Analysguiden publishes research report setting new price target of SEK 39 with an optimistic fair value of at least SEK 80

Non-regulatory pressrelease

Hørsholm, Denmark, March 9, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Analysguiden has updated their research reports on ExpreS2ion in March, following the publication of year-end 2021 results, the release of additional positive Phase II COVID-19 results, and the announcement of the plan to initiate a regulatory validated Phase…

Read more

Pareto publishes research report increasing price target to SEK 99

Non-regulatory pressrelease

Hørsholm, Denmark, March 1, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Pareto Securities has updated their research reports on ExpreS2ion in March, following the publication of year-end 2021 results and the release of additional positive Phase II COVID-19 results for the ABNCoV2 vaccine. Pareto upheld its ‘buy’ rating and…

Read more

Additional positive Phase II COVID-19 results presented for the ABNCoV2 vaccine

Regulatory pressrelease

Hørsholm, Denmark, February 28, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that additional positive results for the ABNCoV2 vaccine, that is being developed as a universal booster vaccine, has been presented from the Phase II clinical trial conducted by Bavarian Nordic. The full study data confirms that existing levels of…

Read more

ExpreS2ion announces financial results for the fourth quarter and full-year 2021

Regulatory pressrelease

Hørsholm, Denmark, February 24, 2022 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its fourth quarter and full year financial results for 2021. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.

Read more

ExpreS2ion provides an update on its novel breast cancer vaccine candidate ES2B-C001

Regulatory pressrelease

Hørsholm, Denmark, February 8, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion" or the “Company”) announces constructive feedback from its scientific advice meeting pertaining to the therapeutic breast cancer vaccine candidate, ES2B-C001, with the Danish Medicines Agency (“DKMA”). Based on this feedback, ExpreS2ion plans to conduct an additional preclinical safety study in…

Read more

ExpreS2ion announces further positive preclinical proof-of-concept results for the HER2-cVLP breast cancer vaccine

Regulatory pressrelease

Hørsholm, Denmark, January 4, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the capsid virus-like particle (cVLP) HER2-breast cancer vaccine candidate ES2B-C001 has demonstrated proof-of-concept also in HER2-transgenic preventive as well as therapeutic tumor mice models. The vaccine has thus reached a further important pre-clinical milestone. These are very important…

Read more

ExpreS2ion announces positive topline results for its HER2-cVLP breast cancer vaccine, demonstrating animal proof-of-concept

Regulatory pressrelease

Hørsholm, Denmark, December 22, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that its capsid virus-like particle (cVLP) breast cancer vaccine candidate ES2B-C001 demonstrated strong tumor-growth inhibiting effect in a mice model, thus reaching an important pre-clinical milestone ahead of schedule. Additionally, anti-HER2 antibodies from these studies were found to effectively…

Read more

ExpreS2ion appoints new Chief Medical Officer

Regulatory pressrelease

Hørsholm, Denmark, December 21, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion” or the “Company”) hereby announces the appointment of Dr. Mattis F. Ranthe as the Company’s new Chief Medical Officer (CMO). Dr. Ranthe brings a decade of broad clinical experience, and he will be responsible for ensuring the progression of ExpreS2ion’s development pipeline activities, including…

Read more

Pareto Securities and Analysguiden publish research reports; Pareto increases price target to SEK 79

Non-regulatory pressrelease

Hørsholm, Denmark, December 9, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Pareto Securities and Analysguiden have updated their respective research reports on ExpreS2ion in December, following the publication of initial results for the phase II testing of ABNCoV2. Pareto reiterated its ‘buy’ rating and increased its target price SEK…

Read more

Positive topline results reported for the Phase II COVID-19 clinical trial with the ABNCoV2 vaccine

Regulatory pressrelease

Hørsholm, Denmark, December 5, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the ABNCoV2 vaccine demonstrated a strong boosting effect in the clinical Phase II trial conducted by Bavarian Nordic. The existing levels of SARS-CoV-2 neutralizing antibodies increased by 2-40-fold, depending on the initial levels of antibodies, with no serious…

Read more

ExpreS2ion will participate in key investor events in December 2021

Non-regulatory pressrelease

Hørsholm, Denmark, November 29, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion") will participate and hold presentations at key investor events in December. These include events hosted by Aktiespararna and HC Andersen Capital in collaboration with Nordea Markets.

Read more

Pareto Securities and Analysguiden publish research reports; Analysguiden increases price target to SEK 60

Non-regulatory pressrelease

Hørsholm, Denmark, November 19, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Pareto Securities and Analysguiden have updated their respective research reports on ExpreS2ion in November, following the publication of Q3 2021 results. Pareto upheld its ‘buy’ rating with a target price of SEK 68 per share, while Analysguiden has…

Read more

ExpreS2ion announces financial results for the third quarter of 2021

Regulatory pressrelease

Hørsholm, Denmark, November 15, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its third quarter financial results for 2021. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.

Read more

ExpreS2ion’s Interim Report for Q3 2021 will be published today

Regulatory pressrelease

Hørsholm, Denmark, November 15, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that the company’s Interim Report for Q3 2021 will be published today, as the report is finalized earlier than planned. The previous date for publication of the report was Thursday, November 18[th], 2021.

Read more

Further efficacy data from the COVID-19 clinical Phase I/II study with ABNCoV2 confirms strong positive results

Regulatory pressrelease

Hørsholm, Denmark, November 12, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the remaining virus neutralization data, for the two highest dose ranges of 50 μg and 70 μg, have now been published from the COUGH-1 COVID-19 Phase I/II clinical trial to evaluate the ABNCoV2 vaccine. The headline results met…

Read more

ExpreS2ion will participate in key investor and industry events in October 2021

Non-regulatory pressrelease

ExpreS2ion Biotech Holding AB (“ExpreS2ion") will participate and hold presentations at key investor and industry events in October. These include events hosted by HC Andersen Capital as well as the World Vaccine Congress and BIO-EUROPE.

Read more

Warrants of series TO5 were subscribed to approximately 97.4 percent and ExpreS2ion receives approximately SEK 44.3 million

Regulatory pressrelease

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SINGAPORE, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES.…

Read more

Last day of trading in warrants of series TO5 is September 16, 2021

Regulatory pressrelease

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm,…

Read more

ExpreS2ion announces TO5 warrant exercise price and start of subscription period

Regulatory pressrelease

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm,…

Read more

ExpreS2ion will participate in key investor events in September 2021

Non-regulatory pressrelease

ExpreS2ion Biotech Holding AB (“ExpreS2ion") will participate and hold presentations at key investor events in September. These include events hosted by LSX Leaders, Aktiespararna, Økonomisk Ugebrev and Dansk Aktionærforening.

Read more

Pareto Securities and Analysguiden publish research reports with increased price targets of SEK 68 and SEK 55, respectively

Non-regulatory pressrelease

Hørsholm, Denmark, August 25, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Pareto Securities and Analysguiden have updated their respective research reports on ExpreS2ion in August. Pareto upheld its ‘buy’ rating with a target price of SEK 68 per share, while Analysguiden has set a new fair value of SEK…

Read more

The ABNCoV2 COVID-19 vaccine program receives up to DKK 800 million from the Danish Ministry of Health

Regulatory pressrelease

Hørsholm, Denmark, August 23, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that Bavarian Nordic, the exclusive licensee of the ABNCoV2 COVID-19 vaccine, will receive up to DKK 800 million in funding from the Danish Ministry of Health for a Phase III trial to confirm safety and demonstrate efficacy as a…

Read more

ExpreS2ion’s Board and Management committed to fully exercise their TO5 warrants

Regulatory pressrelease

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm,…

Read more

COVID-19 Phase II clinical trial initiated to evaluate ABNCoV2 as a booster vaccine

Regulatory pressrelease

Hørsholm, Denmark, August 23, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that a Phase II clinical trial to evaluate the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 vaccine has been initiated by Bavarian Nordic. The trial will investigate the potential of ABNCoV2 as a booster vaccine for individuals with previous…

Read more

Correction: ExpreS2ion announces financial results for the second quarter of 2021

Regulatory pressrelease

Hørsholm, Denmark, August 19, 2021 – This morning ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announced its second quarter financial results for 2021. Some figures were reported incorrectly, specifically the operating income and H1 2020 earnings per share figures reported below in the press release, which are now highlighted in bold. These figures were also incorrect on…

Read more

ExpreS2ion announces financial results for the second quarter of 2021

Regulatory pressrelease

Hørsholm, Denmark, August 19, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its second quarter financial results for 2021. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.

Read more

ExpreS2ion management will present the Q2 2021 interim report via webcast on Thursday, August 19, 2021

Non-regulatory pressrelease

ExpreS2ion Biotech Holding AB (“ExpreS2ion") will present its second quarter 2021 report via a live virtual webcast hosted by HC Andersen Capital on August 19[th], 2021, at 11-11.30hrs.

Read more

Positive safety and efficacy outcome of the COVID-19 clinical Phase I/II study for the ABNCoV2 vaccine

Regulatory pressrelease

Hørsholm, Denmark, August 09, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that COUGH-1, the COVID-19 Phase I/II clinical trial to evaluate the ABNCoV2 vaccine, as headline results has met its safety and efficacy endpoints with excellent virus neutralization levels of up to 12 times higher compared to the levels achieved…

Read more

Update on a new clinical Phase Ib trial for the RH5.1 blood-stage malaria vaccine

Non-regulatory pressrelease

Hørsholm, Denmark, July 21, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that University of Oxford has initiated the VAC080-study, a Phase Ib clinical trial to assess the safety and immunogenicity of the blood-stage Plasmodium falciparum malaria vaccine candidate RH5.1/Matrix-M in adults and infants living in Tanzania.

Read more

ExpreS2ion publishes video from company presentation at a Nordic investor event

Non-regulatory pressrelease

ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that a filmed company presentation by CEO Bent U. Frandsen at the LifeSci Advisors Nordic Biotech Summit investor event on June 29, 2021 is now available on the company’s Vimeo channel.

Read more

Pareto Securities AS initiates equity research coverage of ExpreS2ion with a Buy rating and target price of 60 SEK per share

Non-regulatory pressrelease

Hørsholm, Denmark, June 24, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that Pareto Securities AS has published an equity research initiation report on ExpreS2ion. They initate coverage with a Buy rating and a target price of 60 SEK per share.

Read more

ExpreS2ion will participate in key investor events in June 2021

Non-regulatory pressrelease

ExpreS2ion Biotech Holding AB (“ExpreS2ion") will participate and hold presentations at key investor events in June, all of which will be held digitally. These include HC Andersen Capital’s Life Science Seminar (June 16), and LifeSci Advisors Nordic Biotech Summit (June 29).

Read more

Announcement from ExpreS2ion's annual general meeting

Regulatory pressrelease

The annual general meeting 2021 ("AGM") of ExpreS2ion Biotech Holding AB ("ExpreS2ion" or the "Company") was held today on 26 May 2021 and the following resolutions were passed by the meeting. Due to the ongoing corona pandemic, the AGM was carried out through postal voting only, without physical presence.

Read more

ExpreS2ion Announces Financial Results for the First Quarter of 2021

Regulatory pressrelease

Hørsholm, Denmark, May 19, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its first quarter financial results for 2021. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.

Read more

ExpreS2ion management will present the Q1 2021 interim report via webcast on Wednesday, May 19, 2021

Non-regulatory pressrelease

ExpreS2ion Biotech Holding AB (“ExpreS2ion") will present its first quarter 2021 report via a live virtual webcast hosted by HC Andersen Capital on May 19th, 2021, at 12-12.30hrs.

Read more

Lead candidate selected in ExpreS2ion’s HER2-cVLP breast cancer vaccine project

Regulatory pressrelease

Hørsholm, Denmark, May 11, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces the selection of its lead candidate HER2-cVLP breast cancer vaccine. The project runs according to plan.

Read more

ExpreS2ion - Annual report for 2020 published

Regulatory pressrelease

Hørsholm, Denmark, May 05, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that the company's annual report for the financial year 2020 is published. The annual report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com).

Read more

Warrants of series TO4 were subscribed to approximately 97.6 percent and ExpreS2ion receives approximately SEK 39.0 million

Regulatory pressrelease

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES Hørsholm,…

Read more

ExpreS2ion appoints new Vice President, Business Development

Non-regulatory pressrelease

Hørsholm, Denmark, April 26, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion” or the “Company”) hereby announces that it has appointed Mr. Eske Rygaard-Hjalsted as new Vice President, Business Development. Mr. Rygaard-Hjalsted brings more than 25 years of sales, marketing, and business development experience and will be focused on growing the Company’s commercial foothold, both with…

Read more

Proposal for election of two new members of the Board of Directors

Regulatory pressrelease

Hørsholm, Denmark, April 26, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that Gitte L. Pedersen does not seek re-election to the Board of Directors at the forthcoming Annual General Meeting on May 26, 2021, and that two new members, Karin Garre and Sara Sande, are proposed for election. Thus, it is proposed to…

Read more

Notice of Annual General Meeting in ExpreS2ion Biotech Holding AB

Regulatory pressrelease

The shareholders of ExpreS2ion Biotech Holding AB, reg. no. 559033-3729, (the "Company"), are hereby convened to the annual general meeting to be held on Wednesday 26 May 2021.

Read more

Analysguiden announces new research report with the target price for ExpreS2ion increased to 49 SEK per share

Non-regulatory pressrelease

Hørsholm, Denmark, April 22, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that Aktiespararnars’ Analysguiden has published an updated equity research report on ExpreS2ion. The updated sum-of-the-parts valuation base case increases to 49 SEK per share.

Read more

Publication of clinical Phase I/IIa data in the RH5 blood-stage malaria vaccine

Non-regulatory pressrelease

Hørsholm, Denmark, April 21, 2021 – ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) and its protein production platform ExpreS2™ have contributed to a scientific article published in the journal Med. The article highlights the outcome of the VAC063-study, a Phase I/IIa clinical trial to assess the safety, immunogenicity and efficacy of the blood-stage Plasmodium falciparum malaria vaccine candidate…

Read more

Last day of trading in warrants of series T04 is April 22, 2021

Regulatory pressrelease

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm,…

Read more

Interim safety update on COUGH-1, the COVID-19 clinical phase I/II study for the ABNCoV2 vaccine

Regulatory pressrelease

Hørsholm, Denmark, April 12, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the first group of volunteers in the clinical Phase I/II study, COUGH-1, have been satisfactorily administered with the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 vaccine. The clinical study runs as planned with no untoward safety signal in…

Read more

ExpreS2ion announces T04 warrant exercise price, start of subscription period and Board and Executive Management commitment to fully exercise their T04 warrant holdings

Regulatory pressrelease

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm,…

Read more

ExpreS2ion’s platform (ExpreS2) featured in Viruses article on O-glycosylation on SARS-CoV-2 spike protein

Non-regulatory pressrelease

ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) and its protein production platform ExpreS2™ have contributed to a scientific article published in the journal Viruses. The article describes the site-specific O-glycosylation analysis of SARS-CoV-2 spike protein produced in insect and human cells.

Read more

ExpreS2ion updates on its pipeline outlook, including for COVID-19 and HER2 breast cancer projects

Regulatory pressrelease

Hørsholm, Denmark, March 16, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today presents an updated outlook for its pipeline development projects, including the ABNCoV2 COVID-19 vaccine and its ES2B-C001 HER2-cVLP breast cancer vaccine. The update is published ahead of a digital company presentation to be held today at 11.00 CET, during…

Read more

Approval and initiation of the COVID-19 clinical phase I/II study for the ABNCoV2 vaccine

Regulatory pressrelease

Hørsholm, Denmark, March 8, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the clinical trial application (CTA) for a clinical phase I/II study for the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 vaccine has been approved by the Central Committee on Research Involving Human Subjects (CCMO) in the Netherlands. The…

Read more

ExpreS2ion will participate at key industry and investor events in March 2021

Non-regulatory pressrelease

ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate and hold presentations at key industry and investor events in March, all of which will be held digitally. These include Aktiespararna’s Aktiedagen (March 16), the St. Gallen International Breast Cancer Conference (March 17-21), and BIO-Europe Spring (March 22-25).

Read more

ExpreS2ion Announces 2020 Fourth Quarter and Full-Year Results

Regulatory pressrelease

Hørsholm, Denmark, February 25, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its full-year financial results for 2020 and the fourth quarter of 2020. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.

Read more

ExpreS2ion and University of Bologna announce research collaboration to test HER2-cVLP in state-of-the-art breast cancer mice models

Regulatory pressrelease

Hørsholm, Denmark, February 23, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") and the University of Bologna (“UniBo”) announce a research collaboration agreement (“Agreement”) which covers testing of the novel HER2-cVLP breast cancer vaccine program, including the selected lead candidate ES2B-C001, in proprietary state-of-the-art breast cancer mice models. The collaboration follows the…

Read more

ExpreS2ion’s CEO in interview on achievements in 2020 and the company’s outlook for 2021

Non-regulatory pressrelease

ExpreS2ion Biotech Holding AB (“ExpreS2ion”) publishes an interview with the company’s CEO Bent Frandsen, in which he sums up the company’s achievements in 2021 and the outlook for the rest of 2021 and beyond. This includes discussing the status of the ABNCoV2 COVID-19 vaccine program and the recently in-licensed ES2B-C001 HER2 breast cancer vaccine project.

Read more

ExpreS2ion granted exclusive global license for HER2-cVLP breast cancer vaccine programme from AdaptVac

Regulatory pressrelease

Hørsholm, Denmark, February 2, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the company has today exercised its option to license a unique breast cancer vaccine by signing a final Patent License Agreement (“the Agreement”) with AdaptVac ApS (“AdaptVac”). ExpreS2ion is granted an exclusive global license to a preclinical-stage novel…

Read more

Analysguiden announces new research report with the target price for ExpreS2ion at 24 SEK per share

Non-regulatory pressrelease

Hørsholm, Denmark, January 27, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that Aktiespararnars’ Analysguiden has published an updated equity research report on ExpreS2ion. The updated sum-of-the-parts valuation base case remains at 24 SEK per share.

Read more

Strong preclinical immunization data for the ABNCoV2 cVLP-based COVID-19 vaccine published in Nature Communications

Non-regulatory pressrelease

Today, ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces the publication of strong virus neutralization properties in animal proof-of-concept data for ABNCoV2, a unique capsid virus like particle (cVLP) based COVID-19 vaccine coated with ExpreS2-made SARS-CoV-2 antigens, in the esteemed scientific journal Nature Communications. The ABNCoV2 COVID-19 vaccine is the result…

Read more

ExpreS2ion strengthens its organization to further accelerate its pipeline project development

Regulatory pressrelease

Hørsholm, Denmark, January 11, 2021 – ExpreS2ion Biotech Holding AB hereby announces that its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") is reorganizing the company’s top management to reflect its increased strategic focus on pipeline development. Several appointments within research and development will ensure the advancement of ExpreS2ion’s development projects towards clinical investigations, with the first fully controlled…

Read more

ExpreS2ion announces submission of the COUGH-1 clinical trial application by the Prevent-nCoV consortium and Bavarian Nordic to review ABNCoV2

Regulatory pressrelease

Hørsholm, Denmark, January 8, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the clinical trial application (CTA) for a clinical Phase I/II study for the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 vaccine has been submitted to the Central Committee on Research Involving Human Subjects (CCMO) in the Netherlands. The…

Read more

ExpreS2ion publishes filmed scientific interview on the cVLP COVID-19 vaccine development

Non-regulatory pressrelease

ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that a filmed scientific talk on the development of the cVLP COVID-19 vaccine has been published on the company’s website. The video features Dr. Max M Søgaard from ExpreS2ion and Dr. Ali Salanti from ExpreS2ion’s joint venture and development partner AdaptVac.

Read more

ExpreS2ion carries out new share issue for loan conversion

Regulatory pressrelease

Hørsholm, Denmark, November 27, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that SEK 3.5 million (excluding accrued interest) of the loan provided by Modelio Equity AB (https://news.cision.com/expres2ion-biotechnologies/r/expres2ion-announces-last-part-of-loan-conversion-and-new-loan-facility,c3103406) will be set-off against 331,816 new shares at a price of SEK 10.548 per share (corresponding to a 10 percent discount to the volume weighted average share…

Read more

ExpreS2ion announces interim results for the first nine months of 2020

Regulatory pressrelease

Hørsholm, Denmark, November 19, 2020 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its interim financial results for the first nine months of 2020 and the third quarter of 2020. The Interim Report (Q3) is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.

Read more

ExpreS2ion announces successful manufacturing of the cVLP COVID-19 vaccine and further positive updates

Regulatory pressrelease

Hørsholm, Denmark, November 16, 2020 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the capsid virus like particle (cVLP) based COVID-19 vaccine, which is licensed to Bavarian Nordic, has been successfully manufactured with a full batch release to follow after final quality analysis. The project remains on track for presenting initial…

Read more

First day of trading in warrants of series TO4 and TO5

Regulatory pressrelease

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm,…

Read more

Last day of trading in paid subscribed units (Sw. BTU)

Regulatory pressrelease

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm,…

Read more

ExpreS2ion publishes video from COVID-19-focused company presentation at Japanese event

Non-regulatory pressrelease

ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that a filmed company presentation with CEO Bent U. Frandsen at a digital event in Japan, hosted by the Royal Danish Embassy in Tokyo and Healthcare Denmark, has been published on the company’s website.

Read more

ExpreS2ion publishes video from company presentation at a Danish investor event

Non-regulatory pressrelease

ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that a filmed company presentation by CEO Bent U. Frandsen at a Danish investor event on October 21, 2020 has been published on the company’s website.

Read more

ExpreS2ion’s rights issue oversubscribed

Regulatory pressrelease

THIS PRESS RELEASE IS NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION…

Read more

Last day for subscription in the ongoing rights issue is October 19, 2020

Regulatory pressrelease

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm,…

Read more

ExpreS2ion publishes prospectus in connection with capital raise of up to SEK 216 million

Regulatory pressrelease

THIS PRESS RELEASE IS NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION…

Read more

ExpreS2ion signs commercial license agreement with ABIVAX for using the ExpreS2 platform in their Ebola program

Horsholm, Denmark, April 20, 2017 – Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”), announces that the fully owned subsidiary ExpreS2ion Biotechnologies […]

ExpreS2ion files joint-patent on the production of an improved malaria vaccine with the Walter and Eliza Hall Institute of Medical Research

Horsholm, Denmark, April 6, 2017 – Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”), announces that the fully owned subsidiary ExpreS2ion Biotechnologies […]

ExpreS2ion Biotech Holding AB announces that the OptiFemVac Consortium has received final Eurostars approval of its grant application for development of a novel Zika vaccine

Hørsholm, Denmark, March 30, 2017 – Today, ExpreS2ion Biotech Holding AB announces that the fully owned subsidiary ExpreS2ion Biotechnologies ApS […]

ExpreS2ion’s Licensee, VaxInnate, is Winding Down Operations

Horsholm, Denmark, February 9, 2017 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, […]

ExpreS2ion announces the initial approval of a Eurostars grant application, OptiFemVac, with main focus on the development of a Zika vaccine

Horsholm, Denmark, January 23, 2017 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, […]

ExpreS2ion and ABIVAX announce development collaboration on the Ebola prophylaxis and treatment program, ABX544

Horsholm, Denmark and Paris, France, December 12, 2016 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion […]

ExpreS2ion announces the initiation of a Phase I/IIa clinical trial for a new blood-stage malaria vaccine

Horsholm, Denmark, October 18, 2016 – Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that its collaboration partner, the Jenner Institute […]

ExpreS2ion and VaxInnate Sign Research License Agreement

Horsholm, Denmark, September 20, 2016 – Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”), and VaxInnate Corporation (“VaxInnate”) announce that they have […]

ExpreS2ion Biotech Holding AB: Första dag för handel på Nasdaq Stockholm First North

Idag, den 29 juli 2016, inleds handeln i ExpreS2ion Biotech Holding AB:s (”ExpreS2ion”) aktier på Nasdaq Stockholm First North. Handel […]

ExpreS2ion Biotech announces clinical trial update for the PamVac (Placental Malaria Vaccine) phase I study

ExpreS2ion Biotech announces the second successful evaluation of safety by the independent safety monitoring board for the phase Ia clinical […]

ExpreS2ion Biotech Holding AB approved for listing on Nasdaq Stockholm First North

ExpreS2ion Biotech Holding AB (“ExpreS2ion “) announces that the Company has met the requirements for listing on Nasdaq Stockholm First […]

ExpreS2ion Biotech Holding AB: Listing process delayed

ExpreS2ion Biotech Holding AB herby announces that the listing process at Nasdaq Stockholm First North has been delayed. The company […]

ExpreS2ion Biotech Holding AB’s initial public offering oversubscribed

The 22 June 2016 the subscription period in ExpreS2ion Biotech Holding AB’s (”ExpreS2ion”) initial public offering (”IPO”) of shares at […]

ExpreS2ion Biotech Announces Grant of US Patent

Today, June 21, 2016, ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion Biotech”) announce that its fundamental […]

Today the subscription period of ExpreS2ion Biotech Holding AB’s Initial Public Offering begins

Today, June 8, 2016, the subscription period commences regarding ExpreS2ion Biotech Holding AB’s (“ExpreS2ion”) initial public offering before the planned […]

ExpreS2ion Biotech Holding AB publishes memorandum in advance of the Initial Public Offering

ExpreS2ion Biotech Holding AB (”ExpreS2ion”) hereby publishes the memorandum for the Initial Public Offering which the company plans to commence […]

ExpreS2ion Biotech Holding AB is planning an Initial Public Offering and listing on Nasdaq Stockholm First North

ExpreS2ion Biotech Holding AB (”ExpreS2ion”) hereby announces on May 26th 2016 that the company is planning an Initial Public Offering […]